Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: This study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone. Methods: Thirty-five subjects stabilized on risperidone (3-6 mg/day) for a minimum of 3 months were enrolled in a double-blind,placebo-controlled phase for 12 weeks and an open-label phase for another 12 weeks. Subjects were randomly assigned to receive 10 mg/day aripiprazole (n=17) or placebo (n=18). Over the following 12 weeks, the the aripiprazole group received a flexible dose of aripiprazole while tapering risperidone. At baseline, week 12, and week 24, subjects were evaluated using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Syndrome Rating Scale (ESRS), and standardized neuropsychological assessments. Serum prolactin levels were checked at baseline, week 1, week 2, and week 24. Results: The mean change in total PANSS and cognitive function test scores between baseline and endpoint were similar in the aripiprazole and placebo groups. Scores on the ESRS and negative subscale of PANSS differed significantly between groups in both phases of the study (p＜0.05), indicating a positive effect of aripiprazole. Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015). Conclusion: Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels.
Abstract
Objective: This study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone. Methods: Thirty-five subjects stabilized on risperidone (3-6 mg/day) for a minimum of 3 months were enrolled in a double-blind,placebo-controlled phase for 12 weeks and an open-label phase for another 12 weeks. Subjects were randomly assigned to receive 10 mg/day aripiprazole (n=17) or placebo (n=18). Over the following 12 weeks, the the aripiprazole group received a flexible dose of aripiprazole while tapering risperidone. At baseline, week 12, and week 24, subjects were evaluated using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Syndrome Rating Scale (ESRS), and standardized neuropsychological assessments. Serum prolactin levels were checked at baseline, week 1, week 2, and week 24. Results: The mean change in total PANSS and cognitive function test scores between baseline and endpoint were similar in the aripiprazole and placebo groups. Scores on the ESRS and negative subscale of PANSS differed significantly between groups in both phases of the study (p＜0.05), indicating a positive effect of aripiprazole. Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015). Conclusion: Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels.
참고문헌 (35)
- Green MF, "Cognitive impairment and functional outcome in schizophrenia and bipolar disorder", J Clin Psychiatry, 67, pp.e12~ (2006)
- Lee BJ, "A 12-week, double-blind, placebo- controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia", J Psychopharmacol, 21, pp.421~427 (2007)
- Lee SW, "A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia", Int Clin Psychopharmacol, 22, pp.63~68 (2007)
- Jung Goo Lee, "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study", PSYCHIATRY INVESTIGATION, 9(2), pp.166~173 (2012), 대한신경정신의학회
- Shim JC, "Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial", Neuropsychopharmacology, 37, pp.660~668 (2012)
- Bilder RM, "Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder", Am J Psychiatry, 159, pp.1018~1028 (2002)
- Woodward ND, "A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia", Int J Neuropsychopharmacol, 8, pp.457~472 (2005)
- Byerly M, "Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives", J Clin Psychopharmacol, 27, pp.639~661 (2007)
- Bostwick JR, "Antipsychoticinduced hyperprolactinemia", Pharmacotherapy, 29, pp.64~73 (2009)
- Burris KD, "Aripiprazole, a novel antipsychotic, is a highaffinity partial agonist at human dopamine D2 receptors", JPharmacol Exp Ther, 302, pp.381~389 (2002)
- Tadori Y, "Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors", Eur J Pharmacol, 597, pp.27~33 (2008)
- Jordan S, "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor", Eur J Pharmacol, 441, pp.137~140 (2002)
- Hirose T, "Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile", J Psychopharmacol, 18, pp.375~383 (2004)
- Jordan S, "In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function", Eur J Pharmacol, 483, pp.45~53 (2004)
- Kwon JS, "Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study", Psychiatry Clin Neurosci, 63, pp.73~81 (2009)
- Li Z, "Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain", Eur J Pharmacol, 493, pp.75~83 (2004)
- Mucci A, "Cognitive-enhancing effects of aripiprazole: a case report", Clin Pract Epidemiol Ment Health, 4, pp.24~ (2008)
- Kim SW, "Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia", Clin Neuropharmacol, 32, pp.243~249 (2009)
- Riedel M, "Effect of aripiprazole on cognition in the treatment of patients with schizophrenia", Pharmacopsychiatry, 43, pp.50~57 (2010)
- Riedel M, "Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone", Hum Psychopharmacol, 25, pp.116~125 (2010)
- Suzuki H, "An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.161~168 (2011)
- Kane JM, "A multicenter, randomized, doubleblind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy", J Clin Psychiatry, 70, pp.1348~1357 (2009)
- Yasui-Furukori N, "Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients", J Psychopharmacol, 26, pp.806~812 (2012)
- Shabsigh R, "The Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision as an appropriate diagnostic for premature ejaculation", J Sex Med, 4, pp.1468~1478 (2007)
- Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Chouinard G, "Manual for the Extrapyramidal Symptom Rating Scale", Schizophr Res, 76, pp.247~265 (2005)
- Shim JC, "Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial", Am J Psychiatry, 164, pp.1404~1410 (2007)
- Byerly MJ, "Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study", Schizophr Res, 107, pp.218~222 (2009)
- Chen CK, "Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics", Prog Neuropsychopharmacol Biol Psychiatry, 34, pp.1495~1499 (2010)
- Yasui-Furukori N, "Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia", J Clin Psychopharmacol, 30, pp.596~599 (2010)
- Mace S, "Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder", CNS Drugs, 23, pp.773~780 (2009)
- Agius M, "The staging model in schizophrenia, and its clinical implications", Psychiatr Danub, 22, pp.211~220 (2010)
- Lewandowski KE, "Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder", Psychol Med, 41, pp.225~241 (2011)
- Ojeda N, "Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed", Schizophr Res, 135, pp.72~78 (2012)
- Urichuk L, "Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions", Curr Drug Metab, 9, pp.410~418 (2008)